Multicenter Phase II Study of Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Local control rate
From the date of SABR to the date of local failure or last follow-up
up to 1 year
No
Mi-Sook Kim, MD, PhD
Principal Investigator
Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences
Republic of Korea: Ministry of Food and Drug Safety
K-1205-001-005
NCT01825824
June 2012
December 2016
Name | Location |
---|